A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo

John V. Williams, Zhifeng Chen, Gabriella Cseke, David W. Wright, Christopher J. Keefer, Sharon J. Tollefson, Ann Hessell, Amy Podsiad, Bryan E. Shepherd, Pietro Paolo Sanna, Dennis R. Burton, James E. Crowe, R. Anthony Williamson

    Research output: Contribution to journalArticle

    44 Scopus citations

    Abstract

    Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that is a major cause of lower-respiratory-tract disease. hMPV is associated with more severe disease in infants and persons with underlying medical conditions. Animal studies have shown that the hMPV fusion (F) protein alone is capable of inducing protective immunity. Here, we report the use of phage display technology to generate a fully human monoclonal antibody fragment (Fab) with biological activity against hMPV. Phage antibody libraries prepared from human donor tissues were selected against recombinant hMPV F protein with multiple rounds of panning. Recombinant Fabs then were expressed in bacteria, and supernatants were screened by enzyme-linked immunosorbent assay and immunofluorescent assays. A number of Fabs that bound to hMPV F were isolated, and several of these exhibited neutralizing activity in vitro. Fab DS7 neutralized the parent strain of hMPV with a 60% plaque reduction activity of 1.1 μg/ml and bound to hMPV F with an affinity of 9.8 × 10 -10 M, as measured by surface plasmon resonance. To test the in vivo activity of Fab DS7, groups of cotton rats were infected with hMPV and given Fab intranasally 3 days after infection. Nasal turbinates and lungs were harvested on day 4 postinfection and virus titers determined. Animals treated with Fab DS7 exhibited a >1,500-fold reduction in viral titer in the lungs, with a modest 4-fold reduction in the nasal tissues. There was a dose-response relationship between the dose of DS7 and virus titer. Human Fab DS7 may have prophylactic or therapeutic potential against severe hMPV infection.

    Original languageEnglish (US)
    Pages (from-to)8315-8324
    Number of pages10
    JournalJournal of virology
    Volume81
    Issue number15
    DOIs
    StatePublished - Aug 1 2007

    ASJC Scopus subject areas

    • Microbiology
    • Immunology
    • Insect Science
    • Virology

    Fingerprint Dive into the research topics of 'A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo'. Together they form a unique fingerprint.

  • Cite this

    Williams, J. V., Chen, Z., Cseke, G., Wright, D. W., Keefer, C. J., Tollefson, S. J., Hessell, A., Podsiad, A., Shepherd, B. E., Sanna, P. P., Burton, D. R., Crowe, J. E., & Williamson, R. A. (2007). A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. Journal of virology, 81(15), 8315-8324. https://doi.org/10.1128/JVI.00106-07